- Home
- LGVN vs CVKD Comparison
LGVN vs CVKD Comparison
Compare LGVN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGVN | CVKD |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 20.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LGVN | CVKD |
|---|---|---|
| Price | $0.55 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 473.3K | 69.7K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $7.43 |
| 52 Week High | $2.24 | $22.90 |
Technical Indicators
Market Signals| Indicator | LGVN | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 34.83 |
| Support Level | $0.53 | $7.43 |
| Resistance Level | $0.63 | $12.50 |
| Average True Range (ATR) | 0.05 | 1.10 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 11.74 | 4.82 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.